FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:2362-2363 June 5, 2003 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Baloh, R. W. PubMed Citation

To the Editor: Droperidol (2.5 mg to 10 mg) was mentioned as a treatment option in the Clinical Practice article on vestibular neuritis by Baloh (March 13 issue),¹ with "liver or kidney disease" mentioned as a precaution. In December 2001, the Food and Drug Administration (FDA) strengthened its warnings about the use of droperidol, specifically adding a "black box" warning about deaths associated with prolongation of the QT interval and torsade de pointes. It was recommended that droperidol be reserved for the treatment of patients whose condition was unresponsive to other therapies and that it be used only if the . . . [Full Text of this Article]

This article has been cited by other articles:

• Poelzing, S., Rosenbaum, D. S. (2004). Altered connexin43 expression produces arrhythmia substrate in heart failure. Am. J. Physiol. Heart Circ. Physiol. 287: H1762-H1770 [Abstract] [Full Text]